Perioperative Anticoagulation Management

Direct Oral Anticoagulants (DOACs)

For patients on DOACs undergoing elective surgery, the American College of Cardiology recommends discontinuing apixaban/rivaroxaban 1 day before low-to-moderate bleeding risk procedures and 2 days before high bleeding risk procedures, then resuming 1 day after low-risk or 2-3 days after high-risk surgery, with no bridging anticoagulation recommended 1, 2
For high bleeding risk procedures, apixaban should be stopped 2 days before surgery for patients with normal/mild renal impairment, corresponding to 4 half-lives and minimal residual anticoagulant effect 1, 2
Rivaroxaban should be stopped 48 hours before surgery for high bleeding risk procedures, corresponding to 4 half-lives and 6% residual effect 3
For patients with moderate renal impairment, apixaban discontinuation should be extended to 4 days before high-risk surgery 1
The American College of Cardiology recommends resuming apixaban/rivaroxaban 24 hours postoperatively at usual dose after low bleeding risk surgery, ensuring at least 6 hours have elapsed after the procedure and adequate hemostasis is established 1, 2
After high bleeding risk surgery, apixaban/rivaroxaban should be resumed 48-72 hours postoperatively 1, 2, 3
Consider reduced dose for first 2-3 days in high thromboembolism risk patients: apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily, then advance to full dose 1, 3

For patients on warfarin, the American College of Cardiology recommends stopping warfarin 4-5 days before surgery to allow INR normalization, and reserving therapeutic-dose bridging anticoagulation only for high thromboembolism risk patients 4
High thromboembolism risk patients should be bridged with therapeutic-dose LMWH or unfractionated heparin, discontinued 24 hours before surgery 4
Moderate thromboembolism risk patients should be bridged with prophylactic-dose heparin or LMWH 4
Low thromboembolism risk patients do not require bridging 4
Vitamin K 1-2.5 mg orally can be given 2 days before procedure to reduce off-warfarin period to 2 days, with INR normalizing at time of procedure 4
Postoperatively, warfarin should be resumed when safe, typically 12-24 hours after surgery, along with heparin or LMWH in high thromboembolism risk patients 4

Standard coagulation tests are not useful for monitoring apixaban effect; anti-Xa activity correlates with apixaban exposure if measurement needed 2
For rivaroxaban, measuring prothrombin time with sensitive reagents may confirm low levels before surgery 3
LMWH is not recommended for thromboprophylaxis in patients with prosthetic heart valves, per FDA warning 4
Heparin failures have been reported in pregnant women with mechanical prosthetic valves, possibly reflecting inadequate dosing or inferior efficacy compared to warfarin 4
Postoperative factors like intestinal dysmotility after abdominal surgery affect DOAC absorption 1, 3